OC-0271: 5-Y update of the randomized phase III trial DAHANCA19: Primary (Chemo) RT +/- zalutumumab in HNSCC. (April 2018) - Eriksen, J.G.; Maare, C.; Johansen, J.; Primdahl, H.; Evensen, J.; Kristensen, C.A.; Andersen, L.J.; Overgaard, J.